A phase II, randomised, open-label, three-arm study comparing low-and high-dose Campath® (MabCampath®) and high-dose Rebif® in patients with early, active relapsing-remitting Multiple Sclerosis (MS)

Authors
Category Primary study
Registry of TrialsISRCTN registry
Year 2003
This article has no abstract
Epistemonikos ID: 67bad84ce62a8a136a2f16cfb6a01e498845696f
First added on: Jan 18, 2025